Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathy L Schulman

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Cancer|April 24, 2007
Economic burden of metastatic bone disease in the U.SKathy L Schulman, Joseph Kohles
Current Medical Research and Opinion|October 18, 2007
Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: results from a retrospective population-based studyWilliam A Blumentals, Kathy L Schulman
American Journal of Clinical Oncology|January 7, 2010
Cost comparison of capecitabine in patients with breast cancerHope S Rugo, Joseph Kohles, Kathy L Schulman
Cancer|February 6, 2009
Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancerEdward Chu, Kathy L Schulman, Susan Zelt, et al.
Pediatrics|July 1, 2009
Effects of oseltamivir on influenza-related complications in children with chronic medical conditionsPedro A Piedra, Kathy L Schulman, William A Blumentals
The American Journal of Cardiology|November 26, 2009
Increasing prevalence of atrial fibrillation and flutter in the United StatesGerald V Naccarelli, Helen Varker, Jay Lin, et al.
Clinical Colorectal Cancer|October 6, 2010
Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparisonEdward Chu, Kathy L Schulman, Edward F McKenna, et al.
Thrombosis and Haemostasis|August 5, 2009
Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxisAlpesh N Amin, Jay Lin, Greg Lenhart, et al.
Journal of Thrombosis and Thrombolysis|July 27, 2010
Venous thromboembolism in the US: does race matter?Steven B Deitelzweig, Jay Lin, Barbara H Johnson, et al.
Medscape Journal of Medicine|August 6, 2008
Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005Patrick H Peters, Anne Moscona, Kathy L Schulman, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Cancer|April 24, 2007
Economic burden of metastatic bone disease in the U.SKathy L Schulman, Joseph Kohles
Current Medical Research and Opinion|October 18, 2007
Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: results from a retrospective population-based studyWilliam A Blumentals, Kathy L Schulman
American Journal of Clinical Oncology|January 7, 2010
Cost comparison of capecitabine in patients with breast cancerHope S Rugo, Joseph Kohles, Kathy L Schulman
Cancer|February 6, 2009
Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancerEdward Chu, Kathy L Schulman, Susan Zelt, et al.
Pediatrics|July 1, 2009
Effects of oseltamivir on influenza-related complications in children with chronic medical conditionsPedro A Piedra, Kathy L Schulman, William A Blumentals
The American Journal of Cardiology|November 26, 2009
Increasing prevalence of atrial fibrillation and flutter in the United StatesGerald V Naccarelli, Helen Varker, Jay Lin, et al.
Clinical Colorectal Cancer|October 6, 2010
Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparisonEdward Chu, Kathy L Schulman, Edward F McKenna, et al.
Thrombosis and Haemostasis|August 5, 2009
Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxisAlpesh N Amin, Jay Lin, Greg Lenhart, et al.
Journal of Thrombosis and Thrombolysis|July 27, 2010
Venous thromboembolism in the US: does race matter?Steven B Deitelzweig, Jay Lin, Barbara H Johnson, et al.
Medscape Journal of Medicine|August 6, 2008
Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005Patrick H Peters, Anne Moscona, Kathy L Schulman, et al.
Pageof 3